Neurological function deficits due to cerebral ischemia or neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) have long been considered a thorny issue in clinical treatment. Recovery after neurologic impairment is fairly limited, which poses a major threat to health and quality of life. Accumulating evidences support that ROS and autophagy are both implicated in the onset and development of neurological disorders. Notably, oxidative stress triggered by excess of ROS not only puts the brain in a vulnerable state but also enhances the virulence of other pathogenic factors, just like mitochondrial dysfunction, which is described as the culprit of nerve cell damage. Nevertheless, autophagy is proposed as a subtle cellular defense mode against destructive stimulus by timely removal of damaged and cytotoxic substance. Emerging evidence suggests that the interplay of ROS and autophagy may establish a determinant role in the modulation of neuronal homeostasis. However, the underlying regulatory mechanisms are still largely unexplored. This review sets out to afford an overview of the crosstalk between ROS and autophagy and discusses relevant molecular mechanisms in cerebral ischemia, AD, and PD, so as to provide new insights into promising therapeutic targets for the abovementioned neurological conditions.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2kFGtFg
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
This paper proposes an enhanced ant colony optimization with dynamic mutation and ad hoc initialization, ACODM-I, for improving the accuracy...
-
2016-09-24T01-16-18Z Source: International Journal of Research in Medical Sciences Biswajit Majumder, Viral Tandel, Sandip Ghosh, Sharmis...
-
Antibodies, Vol. 7, Pages 6: In-Depth Comparison of Lysine-Based Antibody-Drug Conjugates Prepared on Solid Support Versus in Solution Anti...
-
Related Articles Long-acting insulin allergy in a diabetic child. Int J Immunopathol Pharmacol. 2017 Apr 01;:394632017700431 Authors...
-
ACS Nano DOI: 10.1021/acsnano.7b02426 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2h1neaG via...
-
No large-scale, head-to-head, phase III, randomized, controlled trial with an adequate sample size has investigated the effect of concurrent...
-
JPM, Vol. 8, Pages 5: Acknowledgement to Reviewers of Journal of Personalized Medicine in 2017 Journal of Personalized Medicine doi: 10.339...
-
Accumulating data have indicated that citrus polymethoxyflavones (PMFs) have the ability to affect brain function. In the present study, we ...
-
Hypopharyngeal Cancer Pharmaceutical and Healthcare Pipeline Review, H1 2017 Medgadget (blog) Latest Pharmaceutical and Healthcare di...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου